Medikamentös-induzierte Kopfschmerzen

Zusammenfassung

Der medikamentös-induzierte Kopfschmerz stellt eine wichtige Differenzialdiagnose von Kopfschmerzerkrankungen dar. Vor dem Hintergrund einer zunehmenden Polypharmazie kann die Kenntnis von potenziell Kopfschmerz-auslösenden Medikamenten helfen, ein Risikoprofil für den einzelnen Patienten zu erstellen. Vasodilatierend wirkende Substanzen, Immuntherapeutika und Zytostatika gehören zu den Medikamenten, die häufiger Kopfschmerzen hervorrufen. Der Kopfschmerz bei Medikamentenübergebrauch stellt eine spezielle Konstellation dar, weil die verursachenden Medikamente eingenommen werden, um bereits bestehende Kopfschmerzen zu behandeln. Der vorliegende Artikel stellt neben einer Synopsis der häufigsten Kopfschmerzauslösenden Medikamente Strategien dar, die eine Behandlung durch Änderung des auslösenden Medikamentes oder eine symptomatische Therapie ermöglichen.

Abstract

Drug-induced headache is an important differential diagnosis among the causes of headache. In view of increasingly frequent polypharmacotherapy the idenfication of potentially headache-inducing drugs may help in the generation of risk profiles for individual patients. Vasodilating substances, immunotherapeutics and immunosuppressive drugs belong to those drugs that often induce headache. Medication overuse headache represents a special constellation, since the causative drugs are used to treat already existing headache. The present article presents a synopsis of the most prevalent headache-inducing drugs as well strategies to overcome drug-induced headache, either by changing the causative drug or by symptomatic therapies.

Schlüsselwörter:

Kopfschmerz - medikamentös-induziert - Medikamentenübergebrauch

Keywords

headache - drug-induced headache - medication overuse

• Literatur

• 1 Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients. A meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205
• 2 Pouyanne P, Haramburu F, Imbs JL et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000; 320: 1036
• 3 Roughead EE, Gilbert AL, Primrose JG et al. Drug-related hospital admissions: a review of Australian studies published 1988–1996. Med J Aust 1998; 165: 405-408
• 4 Benfield P, Clissold SP, Brogden RN. Metoprolol. An updated review of its pharmocodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs 1986; 31: 376-429
• 5 Carter BL. Labetolol. Drug Intell Clin Pharm 1983; 17: 704-712
• 6 Garg KC, Singhal KC, Kumar S. Monitoring the adverse profile of atenolol – a collaborative study. Inian J Physiol Pharmacol 1993; 37: 213-216
• 7 Gonasun LM, Langrall H. Adverse reactions to pindolol administration. Am Heart J 1982; 104: 482-486
• 8 McNeely W, Goa KL. Neivolol in the management of essential hypertension: a review. Drugs 1999; 57: 633-651
• 9 McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol. A review of its pharmacodynamic and pharmokinetic properties, and therapeutic efficacy. Drugs 1993; 45: 232-258
• 10 Prisant LM, Carr AA, Desnoyers M et al. Multicenter evaluation of the hemodynamic effects of bisoprolol in patients with mild to moderate hypertension. J Clin Pharmacol 1990; 30: 1096-1101
• 11 Trippel DL, Gillette PC. Atenolol in children with ventricular arrhythmias. Am Heart J 1990; 119: 1312-1316
• 12 Zanetti LA. Sotalol: a new class III antiarrhythmic agent. Clin Pharm 1993; 12: 883-891
• 13 Homma S, Gilliland Y, Guiney TE et al. Safety of intravenous dipyridamole for stress testing with thallium imaging. Am J Cardiol 1987; 59: 152-154
• 14 Ignaszewski AP, McCormick LX, Heslip PG et al. Safety and clinical utility of combined intravenous dipyridamole/symptom-limited exercise stress test with thallium-201 imaging in patients with known or suspected coronary artery disease. J Nucl Med 1993; 34: 2053-2061
• 15 Laarman GJ, Bruschke AV, Verzijlbergen FJ et al. Efficacy of intravenous dipyridamole with exercise in thallium-201 myocardial perfusion scintigraphy. Eur Heart J 1988; 9: 1206-1214
• 16 Meyers AM, Topham L, Ballow J et al. Adverse reactions to dipyridamole in patients undergoing stress/rest cardiac perfusion testing. J Nucl Med Technol 2002; 30: 21-24
• 17 Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13
• 18 Theis JG, Deichsel G, Marshall S. Rapid development of tolerance to dipyridamole-associated headaches. Br J Clin Pharmacol 1999; 48: 750-755
• 19 Kruuse C, Jacobsen TB, Lassen LH et al. Dipyridamole dilates large cerebral vessles concomitant to headache induction in healthy subjects. J Cereb Blood Flow Metab 2000; 20: 1372-1379
• 20 Chang YJ, Ryu SJ, Lee TH. Dose titration to reduce dipyridamole-related headache. Cerebrovasc Dis 2006; 22: 258-262
• 21 Douen AG, Medic S, Sabih M et al. Titrated initiation of acetylsalicylic acid-dipyridamole therapy reduces adverse effects and improves tolerance in patients with stroke. J Stroke Cerebrovasc Dis 2008; 17: 356-359
• 22 Kruuse C, Jacobsen TB, Lassen LH et al. Dipyridamole dilates large cerebral vessels concomitant to headache induction in healthy subjects. J Cereb Blood flow Metab 2000; 20: 1372-1379
• 23 Bourgeois B, Leppik IE, Sackekkares JC et al. Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology 1993; 43: 693-696
• 24 Faught E, Sachdeo RC, Remler MP et al. Felbamate monotherapy for partial-onset seizures: an active control trial. Neurology 1993; 43: 688-692
• 25 Sachdeo R, Kramer LD, Rosenberg A et al. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992; 32: 386-392
• 26 Ettinger AB, Jandorf L, Berdia A et al. Felbamate-induced headache. Epilepsia 1996; 37: 503-505
• 27 Slaby J, Trneny M, Prochazka B et al. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. Neoplasma 2000; 47: 319-322
• 28 Crucitt MA, Hyman W, Grote T et al. Efficacy and tolerability of oral ondansetron versus prochlorperarine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. Clin Ther 1996; 18: 778-788
• 29 Figueredo ED, Canosa LG. Ondansetron in the prophylaxis of postoperative vomiting: a meta-analysis. J Clin Anesth 1998; 10: 211-221
• 30 Nicolaides C, Giannakakis T, Skarlos D et al. Tropisetron in the prevention of acute nauesa and vomiting in patients treated with high dose epirubicin. J Exp Clin Cancer Res 1998; 17: 71-75
• 31 Tsavaris NB, Koufos C, Katsikas M et al. Pain Symptom Manage. 1999; 18: 218-222
• 32 Van Belle SJ, Stamatakis L, Bleiberg H et al. Dose-finding study of tropisetron in cis-platin induced nausea and vomiting. Ann Oncol 1994; 5: 821-825
• 33 Yarker YE, McTavish D. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs 1994; 48: 761-793
• 34 Koivuranat M, Laara E, Ranta P et al. Comparison of ondansetron and droperidol in the prevention of postoperative nausea and vomiting after laparoscopic surgery in women. A randomised, double-blind, placebo-controlled trial. Acta Anaesthesiol Scand 1997; 41: 1273-1279
• 35 Wymenga AN, van der Graaf WT, Wils JA et al. A randomized, double-blind, mluticentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy. Ann Oncol 1996; 7: 505-510
• 36 Veneziano M, Framarino Dei Malatesta M, Bandiera AF et al. Ondansetron-induced headache. Our experience in gynecological cancer. Eur J Gynaecol Oncol 1995; 16: 203-207
• 37 Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997; 126: 721-730
• 38 Kattamis AC, Shankar S, Cohen AR. Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G. J Pediatr 1997; 130: 281-283
• 39 Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993; 78 (Suppl. 02) 35-40
• 40 Sherer Y, Levy Y, Langevitz P et al. Adverse effects of intravenous immunoglobulin therapy in 50 patients with autoimmune diseases. Pharmacology 2001; 62: 133-137
• 41 Warrier I, Bussel JB, Valdez L et al. Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group. J Pediatr Hematol Oncol 1997; 19: 197-201
• 42 Brannagan TH, Nagle KJ, Lange DJ et al. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996; 47: 674-677
• 43 Stangel M, Kiefer R, Pette M et al. Side effects of intravenous immunoglobulins in neurological autoimmune disorders. A prospective study. J Neurol 2003; 250: 818-821
• 44 Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 2003; 50: 172-175
• 45 Finkel AG, Howard JF, Mann JD. Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications. Headache 1998; 38: 317-321
• 46 Gupta SK, Glue P, Jacobs S et al. Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects. Br J Clin Pharmacol 2003; 56: 131-134
• 47 Riddell LA, Pinching AJ, Hill S et al. A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retroviruses 2001; 17: 789-797
• 48 Coto C, Varela G, Hernandez V et al. Use of recombinant interferon gamma in pediatric patients with advanced juvenile chronic arthritis. Biotherapy 1998; 11: 15-20
• 49 Small EJ, Weiss GR, Malik UK et al. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J Sci Am 1998; 4: 162-167
• 50 Mani S, Todd M, Poo WJ. Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma. AM J Clin Oncol 1996; 19: 187-189
• 51 Kinnula V, Mattson K, Cantell K. Pharmacokinetics and toxicity of inhaled human interferon-alpha in patients with lung cancer. J Interferon Res 1989; 9: 419-423
• 52 Pöllmann W, Erasmus LP, Feneberg W et al. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Neurology 2002; 59: 636-639
• 53 Miller RL, Steis RG, Clark JW et al. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res 1989; 49: 1871-1876
• 54 Walther EU, Hohlfeld R. Multiple sclerosis. Side effects of interferon beta therapy and their management. Neurology 1999; 53: 1622-1627
• 55 Arrigo F, Consolo F. Long-term therapy with slow-release nifedipine in essential hypertension. Cardiovasc Drugs Ther 1990; 4 (Suppl. 05) 941-945
• 56 Cutler NR, Anders RJ, Jhee SS et al. Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. Am J Cardiol 1995; 75: 1102-1106
• 57 Gobel EJ, Hautvast RW, van Gilst WH et al. Randomised, double-blind trial of intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris. Lancet 1995; 346: 1653-1657
• 58 Kirby BJ, Kitchin NR. A comparison of the effects of two modified release preparations of the nifedipine-nifedipine retard 10 mg twice daily and nifedipine GITS 20 mg once daily – in the treatment of mild to moderate hypertension. Int J Clin Pract 1999; 53: 339-343
• 59 Mace PJ, Stallard TJ, Littler WA. Felodipine in hypertension. Eur J Clin Pharmacol 1985; 29: 383-389
• 60 Porcellati C, Verdecchia P, Gatteschi C et al. Ambulatory blood pressure monitoring during sustained treatment with conventional and extended-release felodipine in mild-to-moderate hypertension. Eur J Clin Pharmacol 1989; 37: 555-557
• 61 White WB, Saunders E, Noveck RJ et al. Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. Am J Hypertens 2003; 16: 739-745
• 62 Sunstedt CD, Ruegg PC, Keller A et al. A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension. Am J Med 1989; 86: 98-102
• 63 Batlouni M, Armaganilan D, Ghorayeb N et al. Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients. J Cardiovasc Pharmacol 1992; 19 (Suppl. 03) 53-57
• 64 Luscher TF, Waeber B. Calcium antagonists as first-line therapy in hypertension: results of the Swiss Isradipine Study. J Cardiovasc Pharmacol 1991; 18 (Suppl. 03) 1-3
• 65 Ginsburg R, Lamb IH, Schroeder JS et al. Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm. Am Heart J 1982; 103: 44-49
• 66 Kapoor AS, Gang NS, Reynolds RD. Sustained effects of transdermal nitroglycerin in patients with angina pectoris. Clin Ther 1985; 7: 674-679
• 67 Von Hasselt M, Weiss M, Haase W. Treatment of coronary heart disease with isosorbide mononitrate (Elantan 20). Curr Med Res Opin 1984; 9: 107-112
• 68 Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible molecular mechanisms of migraine pain. Neuroreport 1993; 4: 1027-1030
• 69 Sances G, Tassorelli C, Pucci E et al. Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches. Cephalgia 2004; 24: 110-119
• 70 Ashina M, Bendtsen L, Jensen R et al. Nitric oxide-induced headache in patients with chronic tension-type headache. Brain 2000; 123: 1830-1837
• 71 Christiansen I, Iversen HK, Olesen J. Headache characteristics during the development of tolerance to nitrates: pathophysiological implications. Cephalgia 2000; 20: 437-444
• 72 Govier F, Potempa AJ, Kaufman J et al. A multicenter, randomized, double-blind, cross-over study on patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25: 2709-2723
• 73 Moreira SG, Brannigan RE, Spitz A et al. Side-effect profile of sidenafil citrate (Viagra) in clinical practice. Urology 2000; 56: 474-476
• 74 Raina R, Lakin MM, Agarwal A et al. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: a 3-year follow-up. Urology 2003; 62: 110-115
• 75 Stuckey BG, Jadzinsky MN, Murphy LJ et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003; 26: 279-284
• 76 Goldstein I, Young JM, Fischer J et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed dose study. Diabetes Care 2003; 26: 777-783
• 77 Porst H, Rosen R, Padma-Nathan H et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192-199
• 78 Stroberg P, Murphy A, Costigan T. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter open-label study of patient preference. Clin Ther 2003; 25: 2724-2734
• 79 Kruuse C, Thomsen LL, Jacobsen TB et al. The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J Cereb Blood Flow Metab 2002; 22: 1124-1131
• 80 Kruuse C, Thomsen LL, Birk S et al. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 2003; 126: 241-247
• 81 Bardhan KD, Rensburg C. Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 1585-1591
• 82 Martin RM, Dunn NR, Freemantle S et al. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000; 50: 366-373
• 83 Poole P. Panoprazole. Am J Health Syst Pharm 2001; 58: 999-1008
• 84 Berkowitz RB, Tinkelman DG, Marcoux JP et al. Conversion from twice- to once-daily extended-release theophylline treatment in patients with reversible airway obstruction. J Asthma 1995; 32: 275-284
• 85 Trembath PW, Boobis SW. Plasma theophylline levels after sustained-release aminophylline. Clin Pharmacol Ther 1979; 26: 654-659
• 86 Laursen LC, Johannesson N, Sondergard I et al. Maximally effective plasma concentration of enprofylline and theophyllline during constant infusion. Br J Clin Pharmavol 1984; 18: 591-595
• 87 Atakan N, Erdem C. The efficacy, tolerability and safety of a new oral formulation of Sandimmun – Sandimmun Neoral in severe refractory atopic dermatitis. J Eur Acad Dermatol Venereol 1998; 11: 240-246
• 88 Gijtenbeek JMM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999; 246: 339-346
• 89 Kappers-Klunne MC, van’t Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 2001; 114: 121-125
• 90 Wijdicks EF, Dahlke LJ, Wiesner RH. Oral cyclosporine decreases severity of neurotoxicity in liver transplant recipients. Neurology 1999; 52: 1708-1710
• 91 Maghrabi K, Bohlega S. Cyclosporine-induced migraine with severe vomiting causing loss of renal graft. Clin Neurol Neurosurg 1998; 100: 224-227
• 92 Steiger MJ, Farrah T, Rolles K et al. Cyclosporin associated headache. J Neurol Neurosurg Psychiatry 1994; 57: 1258-1259
• 93 Gryn J, Goldberg J, Viner E. Propranolol for the treatment of cyclosporine-induced headaches. Bone Marrow Transplant 1992; 9: 211-212
• 94 Rozen TD, Wijdicks EF, Hay JF. Treatment-refractory cyclosporine-associated headache: relief with conversion to FK-506. Neurology 1996; 47: 1347
• 95 Fay JW, Wingard JR, Antin JH et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood 1996; 87: 3514-3519
• 96 Sandborn WP. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn’s disease. Am J Gastroenterol 1997; 92: 876-879
• 97 Shapiro R, Fung JJ, Jain AB et al. The side effects of FK-506 in humans. Transpl Proc 1990; 22: 35-36
• 98 Yocum DE, Furst DE, Bensen WG et al. Tacrolimus RA Study Group . Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology 2004; 43: 992-999
• 99 Neuhaus P, McMaster P, Calne R et al. Neurological complications in the European multicenter study of FK 506 and cyclosporin in primary liver transplantation. Transpl Int 1994; 7 (Suppl. 01) 27-31
• 100 Silberstein SD, Olesen J, Bousser M-G et al. The international classification of headache disorders, 2_nd edition (ICHD-II)- revision of criteria for 8.2 medication-overuse headache. Cephalalgia 2005; 25: 460-465
• 101 Diener HC, Dodick DW, Goadsby PJ et al. Chronic migraine-classification, characteristics and treatment. Nat Rev Neurol 2012; 8: 162-171
• 102 Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol 2010; 9: 391-401
• 103 Diener HC, Dahlöf CGH. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA. (eds.). The headaches. 2^nd Edition. Lippincott Williams and Wilkins; Philadephia: 1999: 871-878
• 104 Limmroth A, Katsarava Z, Fritsche G et al. Headache after frequent use of serotonin agonists zolimtriptan and naratriptan. Lancet 1999; 353: 378
• 105 Limmroth A, Katsarava Z, Fritsche G et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59: 1011-1014
• 106 Evers S, Jensen R. Treatment of medication overuse headache – guideline of the EFNS headache panel. Eur J Neurol 2011; 18: 1115-1121
• 107 Katsarava Z, Limmroth V, Finke M et al. Rate and predictors for relapses in medication overuse headache: a one year prospective study. Neurology 2003; 60: 1682-1684
• 108 Katsarava Z, Müssig M, Dzagniza A et al. Rate and predictors for relapses in medication overuse headache: a four year prospective study. Cephalgia 2005; 25: 12-15
• 109 Fritsche G, Eberl A, Katsarava Z et al. Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol 2001; 45: 229-235
• 110 Tribl GG, Schnider P, Wöber C et al. Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache?. Cephalgia 2001; 21: 691-696
• 111 Krings T, Block F, Hans F-J et al. Bildgebende Diagnostik bei der Abklärung des Kopfschmerzes. Dtsch Ärztebl 2004; 101: A3026-A3035